Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.

Keith W Pratz,Mohamad Cherry,Jessica K Altman,Brenda W Cooper,Nikolai A Podoltsev,Jose Carlos Cruz,Tara L Lin,Gary J Schiller,Joseph G Jurcic,Adam Asch,Ruishan Wu,Jason E Hill,Stanley C Gill,Angela J James,Elizabeth Shima Rich,Nahla Hasabou,Alexander E Perl,Mark J Levis

Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2023）

引用 1|浏览24

暂无评分

摘要

These results demonstrated the safety and tolerability of gilteritinib incorporated into an induction and consolidation chemotherapy regimen, and as single-agent maintenance therapy for patients with newly diagnosed -mutant AML. The data herein provide an important framework for the design of randomized trials comparing gilteritinib with other FLT3 inhibitors.

查看译文

关键词

consolidation chemotherapy,aml

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要